Loading...
•
Dec 31, 2024
Prothena Q4 2024 Earnings Report
Prothena reported its financial results for the fourth quarter and full year 2024, highlighting advancements in its protein dysregulation portfolio and providing financial guidance for 2025.
Key Takeaways
Prothena reported a net loss of $58.0 million for the fourth quarter of 2024, an improvement from the $67.5 million net loss in the same period last year. Total revenue for the quarter was $2.1 million, up from $0.3 million in Q4 2023. The company ended the year with $472.2 million in cash, cash equivalents, and restricted cash.
Net cash used in operating and investing activities was $47.8 million in Q4 2024, with a quarter-end cash position of $472.2 million.
Topline results for the confirmatory Phase 3 AFFIRM-AL clinical trial of birtamimab are expected in 2Q 2025.
Multiple clinical readouts for PRX012 from ongoing Phase 1 ASCENT clinical trials are expected starting mid-2025.
Bristol Myers Squibb initiated a Phase 2 clinical trial for BMS-986446 and licensed PRX019 for $80 million.
Prothena
Prothena
Prothena Revenue by Segment
Revenue by Segment
Collaboration Revenue
CapyFin.com Forward Guidance
Prothena expects full year 2025 net cash used in operating and investing activities to be between $168 million and $175 million, with an estimated cash balance of approximately $301 million at year-end. The estimated net loss for 2025 is projected to be between $197 million and $205 million.
Positive Outlook
- Expected cash balance of approximately $301 million at year-end 2025 (midpoint).
- Topline results from confirmatory Phase 3 AFFIRM-AL clinical trial expected in 2Q 2025.
- Multiple clinical readouts for PRX012 from ongoing Phase 1 ASCENT clinical trials expected starting mid-2025 and continuing throughout the year.
- Continued advancement of partnered programs, including BMS-986446 and PRX019.
- Roche continuing to evaluate prasinezumab data for Parkinson's disease.
Challenges Ahead
- Expected net cash used in operating and investing activities of $168 to $175 million for full year 2025.
- Estimated net loss of $197 to $205 million for full year 2025.
- Reliance on clinical trial outcomes for key programs.
- Potential for delays in clinical trial readouts.
- Uncertainty regarding regulatory approvals and commercialization of pipeline assets.